Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
12mon MSN
We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we ...
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...
Makers of copycat versions of Novo Nordisk's (NVO) popular weight-loss drug semaglutide, also known as Ozempic and Wegovy, ...
Compounding pharmacies and telehealth companies selling lower-cost versions of Novo Nordisk's Ozempic and Wegovy will soon have to halt production after the FDA set deadlines to phase out compounded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback